疑似纤维肌痛对中轴型脊柱关节炎十年结局与治疗的影响
基于DESIR队列,采用FiRST问卷每年评估第7至10年,纵向多重插补后定义疑似纤维肌痛阳性。估计患病率为21.7%(144/663;95%CI 18.6-25.1),该状态与更高的自报疾病活动度、更差的生活质量和更严重的残疾相关,且TNF抑制剂启动更频繁但1年留存率更低。
要点
- axSpA中疑似纤维肌痛估计患病率为21.7%(95%CI 18.6-25.1)。
- 疑似纤维肌痛与更高的自报疾病活动度、更差生活质量和更严重残疾持续相关。
- 该组TNFi启动更频繁但1年治疗留存率显著更低(42.0% vs 64.2%)。
核心结论
- 疑似纤维肌痛在axSpA中常见且具有临床相关性,与更高疾病负担、更多生物制剂使用和更差治疗留存相关。
研究设计与样本
- DESIR队列中轴型脊柱关节炎患者,第7至10年每年施测FiRST问卷,缺失数据采用纵向多重插补。
- 插补后至少两次FiRST阳性(FiRST≥5/6)定义为基线疑似纤维肌痛阳性,采用重复测量混合模型和Kaplan-Meier分析评估10年结局与TNFi启动及留存。
主要发现
- 疑似纤维肌痛估计患病率为21.7%(144/663;95%CI 18.6-25.1)。
- 基线时疑似纤维肌痛与较低HLA-B27阳性和放射学骶髂关节炎患病率相关,但MRI骶髂关节炎和CRP升高比例相似。
- 10年间疑似纤维肌痛持续与更高的自报疾病活动度、更差健康相关生活质量和更大残疾相关。
- 10年时永久性残疾在疑似纤维肌痛组更常见(26.4% vs 9.4%;P < .001)。
- 疑似纤维肌痛组TNFi启动更频繁(64.4% vs 46.1%),但1年治疗持续率显著更低(42.0% vs 64.2%)。
关键数值与推荐
- 疑似纤维肌痛阳性定义:插补后FiRST≥5/6至少两次。
- 10年永久性残疾:26.4% vs 9.4%(P < .001)。
- TNFi启动:64.4% vs 46.1%;1年治疗持续率:42.0% vs 64.2%。
临床怎么用
- 对axSpA患者可考虑使用FiRST筛查疑似纤维肌痛以识别高疾病负担和低治疗留存风险人群。
- 疑似纤维肌痛患者TNFi启动更频繁但1年留存率更低,提示需关注治疗决策与随访管理。
局限性
- 疑似纤维肌痛基于FiRST问卷而非临床诊断,且FiRST仅在第7至10年施测,缺失数据经多重插补处理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to evaluate the prevalence of suspected fibromyalgia using the Fibromyalgia Rapid Screening Tool (FiRST) and its impact on disease burden, disability, TNF inhibitor (TNFi) initiation, and treatment retention over 10 years in patients with axial spondyloarthritis (axSpA) from the DESIR cohort. METHODS: The FiRST questionnaire was administered annually from year 7 to year 10. Missing FiRST data were imputed using longitudinal multiple imputation. Patients were classified as suspected fibromyalgia-positive at baseline if they were FiRST-positive (FiRST ≥5/6) at least twice after multiple imputation. Associations with disease outcomes over the 10-year period were assessed using mixed models for repeated measures, adjusted for TNFi use. TNFi initiation and retention over 10 years were compared using Kaplan-Meier analyses. RESULTS: The estimated prevalence of suspected fibromyalgia was 21.7% (144/663; 95% CI: 18.6-25.1). At baseline, suspected fibromyalgia was associated with a lower prevalence of HLA-B27 positivity and radiographic sacroiliitis, but similar rates of magnetic resonance imaging sacroiliitis and elevated C-reactive protein. Over 10 years, suspected fibromyalgia was consistently associated with higher self-reported disease activity, poorer health-related quality of life, and greater disability. Permanent disability at 10 years occurred more frequently in patients with suspected fibromyalgia (26.4% vs 9.4%; P < .001). TNFi initiation was more frequent (64.4% vs 46.1%), but treatment persistence at 1 year was significantly lower (42.0% vs 64.2%) in this group. CONCLUSIONS: Suspected fibromyalgia is common and clinically relevant in axSpA. It is associated with higher disease burden, increased biologic use, and poorer treatment persistence.
引用
- López-Medina C, Chevret S, Lukas C, et al. Prevalence and impact of suspected fibromyalgia on disease outcomes and treatment in axial spondyloarthritis: 10-year follow-up data from the DESIR cohort. Ann Rheum Dis. 2026. PMID: 41794565. doi:10.1016/j.ard.2026.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。